Alaric has been covering the biopharma industry and health care for more than 14 years. His areas of focus include clinical trials, drug development in hematology-oncology, cell and gene therapy and the industry's growing use of artificial intelligence and machine learning. He holds a bachelor's degree in journalism from Ball State University and previously lived in China for three years.
Latest from Alaric DeArment
The drug maker presented data from two cohorts of a pivotal Phase IIb study in NMIBC. Cost and ease of administration offer the potential to benefit the drug commercially.
Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.
The drugmaker said in its first quarter earnings that it did not foresee negative effects on potential approval and launch of lenacapavir for PrEP later this year.
Results from the Phase III HARMONi-6 trial showed the PD-1/VEGF bispecific antibody beating out BeiGene’s Tevimbra in NSCLC.
The company said the main reason for expanding its manufacturing capacity was its growing US commercial portfolio and clinical pipeline.
The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.